Annals of Coloproctology

Display

Sort by :

Original Articles

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting: Chee Young Kim, Sang Hyuk Seo, Min Sung An, Kwang Hee Kim, Ki Beom Bae, Jin Won Hwang, Ji Hyun Kim, Bo Mi Kim, Mi Seon Kang, Min Kyung Oh, Kwan Hee Hong; Ann Coloproctol. 2015;31(3):92-97. Published online June 30, 2015; DOI: https://doi.org/10.3393/ac.2015.31.3.92

5,147 View
41 Download
7 Web of Science
6 Citations

Purpose

The purpose of this study was to identify the excision repair cross-complementation group 1 (ERCC1) as a predictive marker for FOLFOX adjuvant chemotherapy in stages II and III colon cancer patients.

Methods

A total of 166 high risk stages II and III colon cancer patients were retrospectively enrolled in this study, and data were collected prospectively. They underwent a curative resection followed by FOLFOX4 adjuvant chemotherapy. We analyzed ERCC1 expression in the primary colon tumor by using immunohistochemical staining. The oncological outcomes included the 5-year disease-free survival (DFS) rate. The DFS was analyzed by using the Kaplan-Meier method with the log-rank test. A Cox proportional hazard model was used for the prognostic analysis.

Results

ERCC1-positive expression was statistically significant in the older patients (P = 0.032). In the multivariate analysis, the prognostic factors for DFS were female sex (P = 0.016), N stage (P = 0.009), and postoperative carcinoembryonic antigen level (P = 0.001), but ERCC1 expression was not a statistically significant prognostic factor for DFS in the univariate analysis (P = 0.397). The 5-year DFS rate was not significantly associated with the ERCC1 expression in all patients (P = 0.396) or with stage III disease (P = 0.582).

Conclusion

We found that ERCC1 expression was not significantly correlated with the 5-year DFS as reflected by the oncologic outcomes in patients with high-risk stages II and III colon cancer treated with FOLFOX adjuvant chemotherapy.

Citations

Citations to this article as recorded by

ERCC1 and MGMT Methylation as a Predictive Marker of Relapse and FOLFOX Response in Colorectal Cancer Patients from South Tunisia
Dhouha Jamai, Raja Gargouri, Boulbaba Selmi, Abdelmajid Khabir
Genes.2023; 14(7): 1467. CrossRef
EXPRESSION OF NUCLEOTIDE EXCISION REPAIR PROTEIN ERCC1 IN TUMOR TISSUE AS A PROGNOSTIC FACTOR IN COLORECTAL CANCER
Irina Aleksandrovna Bogomolova, Dinara Rishatovna Dolgova, Inna Ivanovna Antoneeva, Ekaterina Gennad'evna Parmenova, Il'seya Rinatovna Myagdieva, Mark Alekseevich Urevskiy
Ulyanovsk Medico-biological Journal.2023; (3): 167. CrossRef
ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy
Aziza E. Abdelrahman, Doaa Abdelaziz Ibrahim, Ahmed El-Azony, Ahmed A. Alnagar, Amr Ibrahim
Cancer Biomarkers.2020; 27(2): 251. CrossRef
Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity
Kai M. Brown, Aiqun Xue, Sohel M. Julovi, Anthony J. Gill, Nick Pavlakis, Jaswinder S. Samra, Ross C. Smith, Thomas J. Hugh
Journal of Surgical Research.2018; 227: 158. CrossRef
Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options
Daniela Rodrigues, Adhemar Longatto-Filho, Sandra F. Martins
BioMed Research International.2016; 2016: 1. CrossRef
ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
Moo-Jun Baek
Annals of Coloproctology.2015; 31(3): 81. CrossRef

Association Between a Close Distal Resection Margin and Recurrence After a Sphincter-Saving Resection for T3 Mid- or Low-Rectal Cancer Without Radiotherapy: Jae Woong Han, Min Jae Lee, Ha Kyung Park, Jae Ho Shin, Min Sung An, Tae Kwun Ha, Kwang Hee Kim, Ki Beom Bae, Tae Hyun Kim, Chang Soo Choi, Sang Hoon Oh, Min Kyung Oh, Mi Seon Kang, Kwan Hee Hong; Ann Coloproctol. 2013;29(6):231-237. Published online December 31, 2013; DOI: https://doi.org/10.3393/ac.2013.29.6.231

5,000 View
23 Download
7 Citations

Abstract PDF

Purpose

To maintain the patient's quality of life, surgeons strive to preserve the sphincter during rectal cancer surgery. This study evaluated the oncologic safety of a sphincter-saving resection with a distal resection margin (DRM) <1 cm without radiotherapy in T3, mid- or low-rectal cancer.

Methods

This retrospective study enrolled 327 patients who underwent a sphincter-saving resection for proven T3 rectal cancer located <10 cm from the anal verge and without radiotherapy between January 1995 and December 2011. The oncologic outcomes included the 5-year cancer-specific survival, the local recurrence, and the systemic recurrence rates.

Results

In groups A (DRM ≤1 cm) and B (DRM >1 cm), the 5-year cancer-specific survival rates were 81.57% and 80.03% (P = 0.8543), the 5-year local recurrence rates were 6.69% and 9.52% (P = 0.3981), and the 5-year systemic recurrence rates were 19.46% and 23.11% (P = 0.5750), respectively.

Conclusion

This study showed that the close DRM itself should not be a contraindication for a sphincter-saving resection for T3 mid- or low-rectal cancer without radiotherapy. However, a prospective randomized controlled trial including the effect of adjuvant therapy will be needed.

Citations

Citations to this article as recorded by

The Impact of Narrow and Infiltrated Distal Margin After Proctectomy for Rectal Cancer on Patients’ Outcomes: a Systematic Review and Meta-analysis
Islam H. Metwally, Mohammad Zuhdy, Omar Hamdy, Ahmed M. Fareed, Saleh S. Elbalka
Indian Journal of Surgical Oncology.2022; 13(4): 750. CrossRef
Association of levels of metabolites with the safe margin of rectal cancer surgery: a metabolomics study
Shaopeng Zhang, Guoqiang Pan, Zhifeng Liu, Yuan Kong, Daguang Wang
BMC Cancer.2022;[Epub] CrossRef
Distal resection margins in rectal cancer specimens: differences in assessment between surgeons and pathologists and the influence of neoadjuvant chemoradiation
T. L. Ghezzi, C. Tarta, P. C. Contu, A. R. Lazzaron, B. M. Contin, L. M. Kliemann, D. C. Damin
Updates in Surgery.2021; 73(5): 1787. CrossRef
Surgical margins in squamous cell carcinoma, different for the vulva?
Noortje Pleunis, Maria E.J. Leermakers, Anneke A. van der Wurff, Paul J.J.M. Klinkhamer, Nicole P.M. Ezendam, Dorry Boll, Joanne A. de Hullu, Johanna M.A. Pijnenborg
European Journal of Surgical Oncology.2018; 44(10): 1555. CrossRef
Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis
SooYoon Sung, Sung Hwan Kim, Joo Hwan Lee, Taek Keun Nam, Songmi Jeong, Hong Seok Jang, Jin Ho Song, Jeong Won Lee, Jung Min Bae, Jong Hoon Lee
International Journal of Radiation Oncology*Biology*Physics.2017; 98(3): 647. CrossRef
Efficacy and Safety of Low-Dose-Rate Endorectal Brachytherapy as a Boost to Neoadjuvant Chemoradiation in the Treatment of Locally Advanced Distal Rectal Cancer: A Phase-II Clinical Trial
Shapour Omidvari, Shadi Zohourinia, Mansour Ansari, Leila Ghahramani, Mohammad Zare-Bandamiri, Ahmad Mosalaei, Niloofar Ahmadloo, Saeedeh Pourahmad, Hamid Nasrolahi, Sayed Hasan Hamedi, Mohammad Mohammadianpanah
Annals of Coloproctology.2015; 31(4): 123. CrossRef
Safe Distal Resection Margin in Patients With T3 Mid and Distal Rectal Cancer Who Underwent a Sphincter-Saving Resection Without Preoperative Radiotherapy
Bong Hwa Lee, Hyoung Chul Park, Min Jeong Kin, Mi Young Jang
Annals of Coloproctology.2013; 29(6): 219. CrossRef

Prognostic Significance of the Decreased Rate of Perioperative Serum Carcinoembryonic Antigen Level in the Patients With Colon Cancer After a Curative Resection: Tae Doo Jung, Jong Han Yoo, Min Jae Lee, Ha Kyung Park, Jae Ho Shin, Min Sung An, Tae Kwun Ha, Kwang Hee Kim, Ki Beom Bae, Tae Hyeon Kim, Chang Soo Choi, Min Kyung Oh, Kwan Hee Hong; Ann Coloproctol. 2013;29(3):115-122. Published online June 30, 2013; DOI: https://doi.org/10.3393/ac.2013.29.3.115

4,624 View
23 Download
4 Citations

Abstract PDF

Purpose

The serum level of carcinoembryonic antigen (CEA) is a clinical prognostic factor in the follow-up evaluation of patients with colon cancer. We aimed to evaluate the prognostic significance of the rate of decrease of the perioperative serum CEA level in patients with colon cancer after a curative resection.

Methods

A total of 605 patients who underwent a curative resection for colon cancer between January 2000 and December 2007 were enrolled retrospectively. The rate of decrease was calculated using the following equation: ([preoperative CEA - postoperative CEA]/[preoperative CEA] ×100).

Results

In the group with a preoperative serum CEA level of >5 ng/mL, the normalized group with a postoperative serum CEA level of ≤5 ng/mL showed a better overall survival (OS) rate and disease-free survival (DFS) rate than those of the non-normalized group (P ≤ 0.0001). The "cutoff values" of the rate of decrease in the perioperative serum CEA that determined the OS and the DFS were 48.9% and 50.8%, respectively. In the multivariate analysis of preoperative serum CEA levels >5 ng/mL, the prognostic factors for the OS and the DFS were the cutoff value (P < 0.0001) and the pN stage (P < 0.0001).

Conclusion

A rate of decrease of more than 50% in the perioperative serum CEA level, as well as the normalization of the postoperative serum CEA level, may be useful factors for determining a prognosis for colon cancer patients with high preoperative CEA levels.

Citations

Citations to this article as recorded by

Patients with T4N0 and T1‑3N1 colon cancer and a high preoperative carcinoembryonic antigen level benefit from adjuvant chemotherapy with oxaliplatin for 6 months
Hiroyuki Inoue, Hiroki Shimizu, Yoshiaki Kuriu, Tomohiro Arita, Kenji Nanishi, Jun Kiuchi, Takuma Ohashi, Yusuke Yamamoto, Hirotaka Konishi, Ryo Morimura, Atsushi Shiozaki, Hisashi Ikoma, Takeshi Kubota, Hitoshi Fujiwara, Eigo Otsuji
Oncology Letters.2024;[Epub] CrossRef
Metastasis of colorectal adenocarcinoma to the mandible
Kushal CHATTERJEE, Aritra CHATTERJEE, Debarati BHOWMICK, Hrishikesh KUMAR, Arif HOSSAIN, Debabrata GAYEN
European Journal of Oral and Maxillofacial Surgery.2021;[Epub] CrossRef
Perioperative Serum Carcinoembryonic Antigen Ratio Is a Prognostic Indicator in Patients With Stage II Colorectal Cancer
Jinsun Woo, Jungbin Kim, Inseok Park, Hyunjin Cho, Geumhee Gwak, Keun Ho Yang, Byung-Noe Bae, Ki Hwan Kim
Annals of Coloproctology.2018; 34(1): 4. CrossRef
Clinicopathologic features and oncologic outcomes of colorectal cancer patients with extremely high carcinoembryonic antigen
Soo Young Lee, Jeong Seon Jo, Hun Jin Kim, Chang Hyun Kim, Jae-Kyun Ju, Young Jin Kim, Hyeong Rok Kim
International Journal of Colorectal Disease.2015; 30(1): 63. CrossRef

Oncologic Outcomes and Risk Factors for Recurrence after Tumor-specific Mesorectal Excision of Rectal Cancer: 782 Cases: Sam Hee Kim, Ki Beom Bae, Jung Min Kim, Jae Ho Shin, Min Sung An, Tae Geun Ha, Sung Mok Ryu, Kwang Hee Kim, Tae Hyeon Kim, Chang Soo Choi, Jin Yong Shin, Minkyung Oh, Seung Hun Baek, Kwan Hee Hong; J Korean Soc Coloproctol. 2012;28(2):100-107. Published online April 30, 2012; DOI: https://doi.org/10.3393/jksc.2012.28.2.100

5,108 View
22 Download
11 Citations

Abstract PDF

Purpose

The aim of this study was to analyze the oncologic outcomes and the risk factors for recurrence after a tumor-specific mesorectal excision (TSME) of resectable rectal cancer in a single institution.

Methods

A total of 782 patients who underwent a TSME for resectable rectal cancer between February 1995 and December 2005 were enrolled retrospectively. Oncologic outcomes included 5-year cancer-specific survival and its affecting factors, as well as risk factors for local and systemic recurrence.

Results

The 5-year cancer-specific survival rate was 77.53% with a mean follow-up period of 61 ± 31 months. The overall local and systemic recurrence rates were 9.2% and 21.1%, respectively. The risk factors for local recurrence were pN stage (P = 0.015), positive distal resection margin, and positive circumferential resection margin (P < 0.001). The risk factors for systemic recurrence were pN stage (P < 0.001) and preoperative carcinoembryonic antigen level (P = 0.005). The prognostic factors for cancer-specific survival were pT stage (P < 0.001), pN stage (P < 0.001), positive distal resection margin (P = 0.005), and positive circumferential resection margin (P = 0.016).

Conclusion

The oncologic outcomes in our institution after a TSME for patients with resectable rectal cancer were similar to those reported in other recent studies, and we established the risk factors that could be crucial for the planning of treatment and follow-up.

Citations

Citations to this article as recorded by

Short-term outcomes of robotic tumor-specific mesorectal resection of rectal cancer: surgical techniques in mesorectal division using rolling division of the mesorectum
Yushi Yamakawa, Nobuhiro Haruki, Nobuo Ochi, Reo Sato, Hiroyuki Asai, Tomohiro Kako, Takumi Kato, Mitsuki Nakazawa, Shuji Takiguchi
Surgical Endoscopy.2024; 38(6): 3478. CrossRef
Current Controversies in the Management of Locally Advanced Colon Cancer
Mishal Gillani, Seth Alan Rosen
The American Surgeon™.2023; 89(8): 3361. CrossRef
Functional outcomes after sphincter-preserving surgeries for low-lying rectal cancer: A review
Eun Jung Park, Seung Hyuk Baik
Precision and Future Medicine.2021; 5(4): 164. CrossRef
Locally Advanced Rectal Cancer Evaluation by Magnetic Resonance Imaging after Neoadjuvant Therapy on Decision Making: Cancer Center Experience and Literature Review
Alejandro Recio-Boiles, Hytham Hammad, Krisha Howell, Bobby T. Kalb, Valentine N. Nfonsam, Aaron J. Scott, Hani M. Babiker, Emad Elquza
Journal of Gastrointestinal Cancer.2020; 51(1): 254. CrossRef
The feasibility of laparoscopic TSME preserving the left colic artery and superior rectal artery for upper rectal cancer
Chi Zhang, Hao-tang Wei, Wenqing Hu, Yueming Sun, Qinyuan Zhang, Masanobu Abe, Zhuoran Du, Yingying Xu, Liang Zong, Xiang Hu
World Journal of Surgical Oncology.2020;[Epub] CrossRef
Recurrence in patients with stage I colorectal cancer
Patrick Ely Teloken, David Ransom, Ian Faragher, Ian Jones, Peter Gibbs, Cameron Platell
ANZ Journal of Surgery.2016; 86(1-2): 49. CrossRef
Current methods in the treatment of rectal cancer
L. Yu. Kazieva, E. G. Rybakov, S. I. Sevostianov
Endoskopicheskaya khirurgiya.2016; 22(4): 49. CrossRef
TRANSANAL TOTAL MESORECTAL EXCISION FOR RECTAL CANCER (review)
L. Uj. Kazieva
Koloproktologia.2016; (2): 57. CrossRef
Anastomotic leakage after curative rectal cancer resection has no impact on long-term survival: a propensity score analysis
Sabrina M. Ebinger, René Warschkow, Ignazio Tarantino, Bruno M. Schmied, Lukas Marti
International Journal of Colorectal Disease.2015; 30(12): 1667. CrossRef
Determinants of recurrence after intended curative resection for colorectal cancer
Michael Wilhelmsen, Thomas Kring, Lars N. Jorgensen, Mogens Rørbæk Madsen, Per Jess, Orhan Bulut, Knud Thygesen Nielsen, Claus Lindbjerg Andersen, Hans Jørgen Nielsen
Scandinavian Journal of Gastroenterology.2014; 49(12): 1399. CrossRef
A Circumferential Resection Margin of 1 mm Is a Negative Prognostic Factor in Rectal Cancer Patients With and Without Neoadjuvant Chemoradiotherapy
Jong Seob Park, Jung Wook Huh, Yoon Ah Park, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee, Ho-Kyung Chun
Diseases of the Colon & Rectum.2014; 57(8): 933. CrossRef

First
Prev
Page of 1
Next
Last

Search